Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab plus best supportive care vs placebo plus best supportive care as second-line treatment in hepatocellular carcinoma after sorafenib
2010-019318-26Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Ramucirumab + best supportive care with Placebo + best supportive care (2 arms). Primary endpoint: Overall survival. Started Jun 2010; status: completed.
02
Drugs
ramucirumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2010-019318-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019318-26.